Management of Patients with Recurrent Glioblastoma using Hypofractionated Stereotactic Radiotherapy
- 19 March 2015
- journal article
- Published by SAGE Publications in Tumori Journal
- Vol. 101 (2), 179-184
- https://doi.org/10.5301/tj.5000236
Abstract
Background: Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. The chance of cure is very limited due to treatment-refractory disease course with frequent recurrences despite aggressive multimodality management. In this retrospective study, we evaluated treatment outcomes of hypofractionated stereotactic radiotherapy (HFSRT) in the management of recurrent GBM and report our single-center experience. Methods: Twenty-eight patients receiving HFSRT for recurrent GBM between September 2008 and February 2014 were retrospectively assessed. Total radiotherapy dose was 25 Gy delivered in 5 fractions over 5 consecutive days for all patients. High-precision, image-guided volumetric modulated arc therapy was delivered with a linear accelerator using 6-MV photons using the frameless technique. Analyzed prognostic factors were age, gender, Karnofsky performance status (KPS), tumor location, planning target volume (PTV) size, overall survival (OS), progression-free survival (PFS), time interval between completion of treatment with Stupp protocol at primary diagnosis and recurrence. Results: Median follow-up time was 42 months (range 2–68). Median time interval between primary chemoradiotherapy and HFSRT was 11.2 months (range 4–57.9). Median OS and PFS calculated from reirradiation was 10.3 months and 5.8 months, respectively. Longer interval between initial treatment and recurrence (p = 0.01), smaller PTV size (p = 0.001), KPS ≥70 (p = 0.005) and younger age (p = 0.004) were associated with longer OS on statistical analysis. Conclusion: HFSRT offers a feasible and effective salvage treatment option for recurrent GBM management. Prognostic factors associated with longer OS in our study were longer interval between initial treatment and recurrence, smaller PTV size, KPS ≥70 and younger age.Keywords
This publication has 40 references indexed in Scilit:
- Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent GlioblastomaJournal of Clinical Oncology, 2013
- Radiation Therapy for the Treatment of Recurrent Glioblastoma: An OverviewCancers, 2012
- A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastomaJournal of Neuro-Oncology, 2010
- BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factorsBMC Cancer, 2010
- Extended-schedule dose-dense temozolomide in refractory gliomasJournal of Neuro-Oncology, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Multi‐institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high‐grade gliomasCancer, 2008
- Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3The Lancet Oncology, 2007
- Astrocyte–endothelial interactions at the blood–brain barrierNature Reviews Neuroscience, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005